Trends in male and female genital warts among adolescents in a safety-net health care system 2004-2013: Correlation with introduction of female and male human papillomavirus vaccination

Sexually Transmitted Diseases

Volumn 42, Issue 12, 2015, Pages 665-668

  Perkins, Rebecca B ^a   Legler, Aaron ^b   Hanchate, Amresh ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CONDYLOMA ACUMINATUM; FEMALE; HEALTH CARE SYSTEM; HEALTH CENTER; HUMAN; ICD-9; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; TREND STUDY; UNITED STATES; VACCINATION; WART VIRUS; CLINICAL TRIAL; CONDYLOMATA ACUMINATA; IMMUNOLOGY; MULTICENTER STUDY; PAPILLOMAVIRUS INFECTIONS; SENTINEL SURVEILLANCE; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASES, VIRAL; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; CONDYLOMATA ACUMINATA; FEMALE; HUMANS; INTERRUPTED TIME SERIES ANALYSIS; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SENTINEL SURVEILLANCE; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASES, VIRAL; SOCIOECONOMIC FACTORS; UNITED STATES; VACCINATION; YOUNG ADULT;

EID: 84947866701     PISSN: 01485717     EISSN: 15374521     Source Type: Journal    
DOI: 10.1097/OLQ.0000000000000369     Document Type: Article

References (25)

1. Ault KA. Epidemiology and natural history of human papillomavirus infections in the female genital tract. Infect Dis Obstet Gynecol 2006; 14:40470.
2. Flagg EW, Schwartz R, Weinstock H. Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: Potential impact of human papillomavirus vaccination. Am J Public Health 2013; 103:1428-1435.
3. Leval A, Herweijer E, Arnheim-Dahlström L, et al. Incidence of genital warts in Sweden before and after quadrivalent human papillomavi-rus vaccine availability. J Infect Dis 2012; 206:860-866.
4. Read TR, Hocking JS, Chen MY, et al. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011; 87:544-547.
5. Nsouli-Maktabi H, Ludwig SL, Yerubandi UD, et al. Incidence of genital warts among U.S. service members before and after the introduction of the quadrivalent human papillomavirus vaccine. MSMR 2013; 20:17-20.
6. Kahn JA, Lan D, Kahn RS. Sociodemographic factors associated with high-risk human papillomavirus infection. Obstet Gynecol 2007; 110: 87-95.
7. Kahn JA, Brown DR, Ding L, et al. Vaccine-type human papillomavi-rus and evidence of herd protection after vaccine introduction. Pediatrics 2012; 130:249-256.
8. Brogly SB, Perkins RB, Zepf D, et al. Human papillomavirus vaccination and cervical cytology in young minority women. Sex Transm Dis 2014; 41:511-514.
9. Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent human pap-illomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2007; 56: 1-24.
10. Centers for Disease Control and Prevention (CDC). FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010; 59:630-632.
11. Centers for Disease Control and Prevention (CDC). Recommendations on the use of quadrivalent human papillomavirus vaccine in males-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011; 60:1705-1708.
12. Wagner AK, Soumerai SB, Zhang F, et al. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002; 27:299-309.
13. Bauer HM, Wright G, Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-2010. Am J Public Health 2012; 102:833-835.
14. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009; 339:b3884.
15. Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: National surveillance data. BMJ 2013; 346:f2032.
16. Smith MA, Liu B, McIntyre P, et al. Fall in genital warts diagnoses in the general and indigenous Australian population following implementation of a national human papillomavirus vaccination program: Analysis of routinely collected national hospital data. J Infect Dis 2015; 211:91-99.
17. Chow EP, Read TR, Wigan R, et al. Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papil-lomavirus (HPV) vaccination programme. Sex Transm Infect 2015; 91:214-219.
18. Gertig DM, Brotherton JM, Budd AC, et al. Impact of a population-based HPV vaccination program on cervical abnormalities: A data linkage study. BMC Med 2013; 11:227.
19. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365:1576-1585.
20. Centers for Disease Control and Prevention (CDC). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010; 59:626-629.
21. Drolet M, Brisson M, Maunsell E, et al. The impact of anogenital warts on health-related quality of life: A 6-month prospective study. Sex Transm Dis 2011; 38:949-956.
22. Senecal M, Brisson M, Maunsell E, et al. Loss of quality of life associated with genital warts: Baseline analyses from a prospective study. Sex Transm Infect 2011; 87:209-215.
23. Olsen J, Jorgensen TR. Revisiting the cost-effectiveness of universal HPV-vaccination in Denmark accounting for all potentially vaccine preventable HPV-related diseases in males and females. Cost Eff Resour Alloc 2015; 13:4.
24. Presidents Cancer Panel. President's Cancer Panel Annual Report 2012-2013: Accelerating HPV vaccine uptake: urgency for action to prevent cancer. 2014 Available at: http://deainfo.nci.nih.gov/ADVISORY/pcp/annualReports/HPV/index.htm-sthash.VFWWaxYh.dpbs. Accessed February 24, 2014.
25. Leval A, Herweijer E, Ploner A, et al. Quadrivalent human papilloma-virus vaccine effectiveness: A Swedish national cohort study. J Natl Cancer Inst 2013; 105:469-474.